Pharmacological and nutritional treatment for McArdle disease (Glycogen Storage Disease type V)

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 11, 2014, Pages

  Quinlivan, Rosaline ^a   Martinuzzi, Andrea ^b   Schoser, Benedikt ^c  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b Medea Scientific Institute   (Italy)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BRANCHED CHAIN AMINO ACID; CREATINE; CREATINE KINASE; DANTROLENE; DIPEPTIDYL CARBOXYPEPTIDASE; GLUCAGON; PYRIDOXINE; RAMIPRIL; RIBOSE; SUCROSE; VERAPAMIL; CARBOHYDRATE DIET; PROTEIN INTAKE;

AEROBIC CAPACITY; CARBOHYDRATE DIET; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DIET THERAPY; DISABILITY; DISEASE SEVERITY; DIZZINESS; DNA POLYMORPHISM; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG THERAPY; ENDURANCE; EXERCISE; FATIGUE; FUNCTIONAL ASSESSMENT; GLYCOGEN STORAGE DISEASE TYPE 5; HUMAN; HUNGER; HYPOGLYCEMIA; LOW DRUG DOSE; MUSCLE METABOLISM; MUSCLE STRENGTH; MUSCLE WEAKNESS; MYALGIA; MYOGLOBINURIA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DIET; QUALITY OF LIFE; QUASI EXPERIMENTAL STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SOMNOLENCE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; WALKING SPEED; ADMINISTRATION AND DOSAGE; DIETARY SUPPLEMENT; GLYCOGEN STORAGE DISEASE TYPE V; META ANALYSIS; PROTEIN INTAKE;

CREATINE; DIETARY CARBOHYDRATES; DIETARY PROTEINS; DIETARY SUPPLEMENTS; GLYCOGEN STORAGE DISEASE TYPE V; HUMANS; PHYSICAL ENDURANCE; RAMIPRIL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SUCROSE;

EID: 84994102519     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD003458.pub5     Document Type: Review

References (60)

1. Andersen ST, Vissing J. Carbohydrate- and protein-rich diets in McArdle disease: effects on exercise capacity. Journal of Neurology, Neurosurgery & Psychiatry 2008;79(12):1359-63. [PUBMED: 19010947].
2. Andersen ST, Haller RG, Vissing J. Effect of oral sucrose before exercise on work capacity in McArdle disease. Archives of Neurology 2008;65(6):786-9. [PUBMED: 18541798].
3. Beynon RJ, Quinlivan RCM, Hopkins P, White L, Bartram C, Phoenix J. McArdle's disease: molecular genetics, clinical heterogeneity and a therapeutic trial. Muscle & Nerve 1998;30 Suppl:30.
4. Day TJ, Mastaglia FL. Depot-glucagon in the treatment of McArdle's disease. Australian and New Zealand Journal of Medicine 1985;15(6):748-50. [PUBMED: 3869441].
5. Kushner RF, Berman SA. Are high-protein diets effective in McArdle's Disease?. Archives of Neurology 1990;47(4):383-4. [PUBMED: 2322130].
6. Lane RJ, Turnbull DM, Welch JL, Walton J. A double-blind placebo-controlled crossover study of verapamil in exertional muscle pain. Muscle & Nerve 1986;9(7):635-41. [PUBMED: 3531845].
7. MacLean D, Vissing J, Vissing SF, Haller RG. Oral branched-chain amino acids do not improve exercise capacity in McArdle disease. Neurology 1998;51(5):1456-9. [PUBMED: 9818881].
8. Martinuzzi A, Liava A, Trevisi E, Antoniazzi L, Frare M. Chronic therapy for McArdle disease: the randomized controlled trial with ACE inhibitor. Acta Myologica 2007;26(1):64-6. [PUBMED: 17915574].
9. Martinuzzi A, Liava A, Trevisi E, Frare M, Tonon C, Malucelli E, et al.Randomised, placebo-controlled, double-blind pilot trial of ramipril in McArdle's disease. Muscle & Nerve 2008;37(3):350-7. [PUBMED: 18098237].
10. Poels PJ, Braakhekke JP, Joosten EM, Stegeman DF. Dantrolene sodium does influence the second-wind phenomenon in McArdle's disease. Electrophysioloical evidence during exercise in a double-blind placebo-controlled, cross-over study in 5 patients. Journal of the Neurological Sciences 1990;100(1-2):108-12. [PUBMED: 2089128].
11. Steele IC, Patterson VH, Nicholls DP. A double blind, placebo controlled, crossover trial of D-ribose in McArdle's disease. Journal of the Neurological Sciences 1996;136(1-2):174-7. [PUBMED: 8815168].
12. Vissing J, Haller RG. The effect of oral sucrose on exercise tolerance in patients with McArdle's disease. New England Journal of Medicine 2003;349(26):2503-9. [PUBMED: 14695410].
13. Vorgerd M, Grehl T, Jager M, Muller K, Freitag G, Patzold T, et al.Creatine therapy in myophosphorylase deficiency (McArdle disease). A placebo-controlled crossover trial. Archives of Neurology 2000;57(7):956-63. [PUBMED: 10891977].
14. Vorgerd M, Zange J, Kley R, Grehl T, Husing A, Jager M, et al.Effect of high-dose creatine therapy on symptoms of exercise intolerance in McArdle disease: double-blind, placebo-controlled crossover study. Archives of Neurology 2002;59(1):97-101. [PUBMED: 11790236].
15. Andersen ST, Jeppesen TD, TaivassaloT, Sveen ML, Heinicke K, Haller RG, et al.Effect of changes in fat availability on exercise capacity in McArdle disease. Archives of Neurology 2009;66(6):762-6.
16. Busch V, Gempel K, Hack A, Muller K, Vorgerd M, Lochmuller H, et al.Treatment of glycogenosis type V with ketogenic diet. Annals of Neurology 2005;58(2):341.
17. Haller RG, Vissing J. Spontaneous "second wind" and glucose-induced "second wind" in McArdle disease. Archives of Neurology 2002;59(9):1395-402.
18. Jensen KE, Jacobson J, Thomsen C, Henriksen O. Improved energy kinetics following high protein diet in McArdle's syndrome. A 31P magnetic resonance spectroscopy study. Acta Neurologica Scandinavica 1990;81(6):499-503.
19. Kono N, Mineo I, Sumi S, Shimizu T, Kang J, Nonaka K, et al.Metabolic basis of improved exercise tolerance: Muscle phosphorylase deficiency after glucagon administration. Neurology 1984;34(11):1471-76.
20. Lewis SF, Haller RG, Cook JD, Nunnally RL. Muscle fatigue in McArdle's disease studied by 31P-NMR: effect of glucose infusion. Journal of Applied Physiology 1985;59(6):1991-4.
21. Mineo I, Kono N, Shimizu T, Sumi S, Nonaka K, Tarui S. A comparative study on glucagon effect between McArdle disease and Tarui disease. Muscle & Nerve 1984;7(7):552-9.
22. O'Reilly DS, Carter R, Bell E, Hinnie J, Galloway PJ. Exercise to exhaustion in the second-wind phase of exercise in case of McArdle's disease with and without creatine supplementation. Scottish Medical Journal 2003;48(2):46-8.
23. Phoenix J, Hopkins P, Bartram C, Beynon R, Quinlivan RC, Edwards RHT. Effect of vitamin B6 supplementation in McArdle's disease: a strategic case study. Neuromuscular Disorders 1998;8(3-4):210-2.
24. Schoser B. Individual patient data (supplied 2008). Data on file.
25. Schroers A, Kley R, Stachon A, Horvath R, Lochmuller H, Gange J, et al.Gentamicin treatment in McArdle disease: failure to correct myophosphorylase deficiency. Neurology 2006;66(2):285-6.
26. Slonim A E, Goans PJ. Myopathy in McArdle's syndrome: improvement with a high protein diet. New England Journal of Medicine 1985;312(6):355-9.
27. Viskoper R, Wolf E, Chaco J, Katz R, Chowers I. McArdle's syndrome: the reaction to a fat rich diet. American Journal of Medical Sciences 1975;269(2):217-21.
28. Vorgerd M, Zange J. Treatment of glycogenosys type V (McArdle disease) with creatine and ketogenic diet with clinical scores and with 31P-MRS on working leg muscle. Acta Myologica 2007;26(2):61-3.
29. Wagner D R, Zollner N. McArdle's disease: successful symptomatic therapy by high dose oral administration of ribose. Klinische Wochenschrift 1991;69(2):92.
30. Andreu A, Nogales-Gadea G, Cassandrini D, Arenas J, Bruno C. McArdle disease: molecular genetic update. Acta Myologica 2007;26(1):53-7.
31. Barton-Davis ER, Cordier L, Shoturma DI, Leland SE, Sweeney HL. Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. Journal of Clinical Investigation 1999;104(4):375-81.
32. Bartram C, Edwards RHT, Clague J, Beynon R. McArdle's disease: a nonsense mutation in exon 1 of the muscle glycogen phosphorylase gene explains some but not all cases. Human Molecular Genetics 1993;2(8):1291-3.
33. Bertorini T, Palmieri G, Bhattacharya S. Beneficial effects of dantrolene sodium in exercise-induced muscle pains: calcium mediated?. Lancet 1982;1(8272):616-7.
34. Beynon RJ, Bartram C, Hopkins P, Toesco V, Gibson H, Phoenix J, et al.McArdle's disease: molecular genetics and metabolic consequences of the phenotype. Muscle & Nerve 1995;3:S18-22.
35. Borg GA. Psychophysical bases of perceived exertion. Medicine and Science in Sports and Exercise 1982;14(5):377-81.
36. De Stefano N, Argov Z, Matthews PM, Karpati G, Arnold DL. Impairment of muscle mitochondrial oxidative metabolism in McArdle's disease. Muscle & Nerve 1996;19(6):764-9.
37. Gómez-Gallego F, Santiago C, Morán M, Perez M, Maté-Munoz JL, Fernández Del Valle M, et al.The I allele of the ACE gene is associated with improvement in exercise capacity in women with McArdle disease. British Journal of Sports Medicine 2008;42:134-40.
38. Haller R G, Dempsey W B, Feit H, Cook J D, Knochel JP. Low levels of muscle pyridoxine in McArdle's syndrome. American Journal of Medicine 1983;74(2):217-20.
39. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2009. Available from www.cochrane-handbook.org.
40. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
41. Kubisch C, Wicklein EM, Jentsch TJ. Molecular diagnosis of McArdle's disease: revised genomic structure of the phosphorylase gene and identification of a novel mutation. Human Mutation 1998;12:27-32.
42. Libonati JR, Cox M, Incanno N, Melville SK, Musante FC, Glassberg HL, et al.Brief periods of occlusion and re-perfusion increase skeletal muscle force output in humans. Cardiologia 1998;43(12):1355-60.
43. Lucia A, Gomez-Gallego F, Santiago C, Perez M, Mate-Munoz JL, Chamorro-Vina C, et al.The 577X allele of the ACTN3 gene is associated with improved exercise capacity in women with McArdle's disease. Neuromuscular Disorders 2007;17(8):603-10.
44. Martinuzzi A, Sartori E, Fanin M, Nascimbeni A, Valente L, Angelini C, et al.Phenotype modulators in myophosphorylase deficiency. Annals of Neurology 2003;53(4):497-502.
45. McArdle B. Myopathy due to a defect in muscle glycogen breakdown. Clinical Science 1951;10:13-33.
46. Mommaerts WFH, Illingworth B, Pearson CM, Guilorg RJ, Seraydarian K. A functional disorder of muscle associated with the absence of phosphorylase. Proceedings of the National Academy of Science USA 1959;3:18-22.
47. Orngreen MC, Jeppesen TD, Andersen ST, Taivassalo T, Hauerslev S, Priesler N, et al.Fat metabolism during exercise in patients with McArdle disease. Neurology 2009;72(8):718-24.
48. Pearson CM, Rimor DG, Mommaerts WFHM. A metabolic myopathy due to absence of muscle phosphorylase. American Journal of Medicine 1961;30:502-17.
49. Quinlivan R, Vissing J, Hilton-Jones D, Buckley J. Physical training for McArdle disease. Cochrane Database of Systematic Reviews 2011, Issue 12. [DOI: 10.1002/14651858.CD007931.pub2].
50. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
51. Rubio JC, Gomez-Gallego F, Santiago C, Garcia-Consuegra I, Perez M, Barriopedro MI, et al.Genotype modulators of clinical severity in McArdle disease. Neuroscience Letters 2007;422(3):217-22.
52. Ruff RL. Why do patients with McArdle's disease have decreased exercise capacity?. Neurology 1998;50(1):6-7.
53. Schmidt R, Mahler R. Chronic progressive myopathy with myoglobinuria: demonstration of a glycogenolytic defect in muscle. Journal of Clinical Investigation 1959;108:2044-58.
54. Tarnopolsky MA, Roy BD, MacDonald JR. A randomised controlled trial of creatine monohydrate in patients with mitochondrial cytopathies. Muscle & Nerve 1997;20:1502-9.
55. Vandenberghe K, Goris M, Van Hecke P, Van Leemputte M, Vangerven L, Hespel P. Long term creatine intake is beneficial to muscle performance during resistance training. Journal of Applied Physiology 1997;83(6):2055-63.
56. Vissing J, Vissing SF, Maclean D, Saltin B, Quistorff B, Haller RJ. Sympathetic activation in exercise is not dependent on muscle acidosis. Direct evidence from studies in metabolic myopathies. Journal of Clinical Investigation 1998;108(8):1654-60.
57. Quinlivan RCM, Beynon R. Pharmacological and nutritional treatment for McArdle's disease (Glycogen storage disease type V). Cochrane Database of Systematic Reviews 2002, Issue 1. [DOI: 10.1002/14651858.CD003458].
58. Quinlivan R, Beynon RJ. Pharmacological and nutritional treatment for McArdle's disease (Glycogen Storage Disease type V). Cochrane Database of Systematic Reviews 2004, Issue 3. [DOI: 10.1002/14651858.CD003458.pub2].
59. Quinlivan R, Beynon RJ, Martinuzzi A. Pharmacological and nutritional treatment for McArdle disease (Glycogen Storage Disease type V). Cochrane Database of Systematic Reviews 2008, Issue 2. [DOI: 10.1002/14651858.CD003458.pub3].
60. Quinlivan R, Martinuzzi A, Schoser B. Pharmacological and nutritional treatment for McArdle disease (Glycogen Storage Disease type V). Cochrane Database of Systematic Reviews 2010, Issue 12. [DOI: 10.1002/14651858.CD003458.pub4].